Akèy › Kansè Glann Salivè › Texas
Etid klinik pou Kansè Glann Salivè nan Texas
6 etid pou Kansè Glann Salivè ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
DESTINY-PANTUMOUR04
- Research Site, Dallas
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05884320A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- Baylor St. Luke's Medical Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2026 · NCT03740256VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- The University of Texas MD Anderson Cancer Center (site 127), Houston
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Dec 11, 2025 · NCT03556228A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.